Medical Cannabis Price: Are Expensive Strains Really Better?

In short: Medical Cannabis Price at a Glance

The price of medical cannabis results from several factors. The gram price is therefore not comparable to a simple quality rating.

The most important price factors include:

Germany is supplied with medicinal cannabis both from domestic production and imports. Pharmacies can obtain corresponding products from various manufacturers and importers. This results in different purchase prices even for comparable THC levels.

Current availability also plays a major role. A strain may temporarily become more expensive if only small quantities are available or an importer cannot resupply. However, this does not automatically make it more effective.

Concrete Price Comparison

The assortment of specialized pharmacies can often be divided into three price ranges: under 5 euros, between 5 and 10 euros, and over 10 euros per gram.

Between the cheapest and the most expensive example, with a monthly quantity of 30 grams, there is a difference of 240.30 Euros. Calculated annually, that would be 2,883.60 Euros.

This shows why the medical cannabis price for self-payers can play a significant role. Nevertheless, it would be wrong to always opt for the cheapest strain. A poorly suited strain can lead to more applications, more frequent changes, or a higher required quantity.

Self-payer or cost coverage?

For those with statutory health insurance, the situation is particularly important. Cannabis medications can be covered by health insurance under certain conditions. These conditions notably include a severe illness, a lack of suitable alternative therapies, and the prospect of a noticeable positive impact on symptoms.

However, statutory requirements and reimbursement regulations can change. Patients with existing or planned cost coverage should therefore clarify the current status directly with their health insurance company and their treating practice. (As of: July 23, 2026)

Other cannabis medications, such as standardized extracts or medications with dronabinol or nabilon, are distinct from cannabis flowers. Which costs can be covered in individual cases must be medically reviewed and clarified with the responsible health insurance company.

Many patients initially compare strains based on their THC content. A flower with 30 or 34 percent THC appears stronger at first glance and therefore potentially more valuable than a strain with 18 percent.

For medical selection, this view is too simplistic. A high percentage initially only describes the active ingredient concentration of the flower. It does not indicate how much a patient needs, how well the strain is tolerated, or whether it is suitable for the particular therapeutic goal.

The myth of "strong" cannabis

More THC does not automatically mean more therapeutic benefit. High-potency cannabis products can be associated with an increased risk of undesirable psychological and physical effects. Therefore, the general principle is often to aim for the lowest individually effective dosage.

Very high THC levels can, among other things, promote undesirable reactions such as restlessness, dizziness, concentration problems, or an unpleasantly intense effect. Furthermore, tolerance can develop with regular use. Then a larger quantity may be needed for a comparable effect.

Economically, therefore, it is not the highest THC value that is decisive, but the required daily amount.

Simplified example calculation:

• Strain A costs 4 euros per gram and is used at 0.30 grams per day: 1.20 euros per day

• Strain B costs 8 euros per gram and is used at 0.12 grams per day: 0.96 euros per day

Whether a smaller amount is actually sufficient is individual and must be assessed by a doctor. But the example shows: The more expensive strain per gram can theoretically lead to lower daily costs.

The more meaningful value is therefore:

Price per gram × actual daily dose required = therapy costs per day

The role of terpenes

Terpenes are aromatic plant compounds that define the smell and taste of a strain. They are often also attributed an influence on the overall effect. There are interesting scientific approaches for this so-called entourage effect, but clinical evidence is still limited.

Therefore, it cannot be reliably deduced from a single terpene whether a strain is calming, activating, or suitable for a specific medical condition.

Nevertheless, the terpene profile can be a useful comparison feature – especially if a patient has already documented which strains they tolerate well. However, it should not be understood as a fixed promise of effect.

Perhaps the most important difference to the unregulated market of the past is that medical cannabis flowers from pharmacies are subject to binding pharmaceutical regulations.

For cannabis flowers, requirements include active ingredient content, potential contaminants, foreign matter, and pharmaceutical quality. These basic requirements apply not only to expensive products.

A cheap pharmacy flower is therefore not comparable to an uncontrolled product of unknown origin. The lower price does not automatically mean that laboratory tests or pharmaceutical standards have been omitted.

However, differences can still exist, for example, in:

• Residual moisture and flower texture

• Size and structure of individual flowers

• Intensity of smell and taste

• Packaging and storage

• Availability of consecutive batches

• Fluctuations within permissible specifications

• Personal perception and tolerance

These characteristics can be relevant for patients. However, they do not automatically justify every price premium.

International studies on deviations between declared and measured THC values must also be correctly classified. Results from foreign recreational markets cannot be easily transferred to German pharmacy products.

For German patients, therefore, batch-specific analyses, proper storage, and personal therapy documentation are more informative than general experience reports from other markets.

Why patients often choose incorrectly

A common mistake is selecting based on only a single characteristic:

• Highest possible THC content

• Lowest possible price

• Known manufacturer

• Particularly intense smell

• Recommendation from a forum

• Designations like "Indica" or "Sativa"

None of these characteristics alone is sufficient to assess medical suitability.

Particularly important are the therapeutic goal, the prescribed dosage, possible concomitant diseases, other medications, previous experience with THC, and the type of application. Even a product that is positively rated by many other patients may be individually unsuitable.

The medical cannabis price can be a selection criterion – but not the only one. A comparison based on several practical factors is more informative.

• Traceable active ingredient profile
  THC and CBD content should be clearly stated. If available, batch-specific information and terpene profile data can also help with documentation.
• Reproducible effect
  What matters is not whether a strain has a particularly intense effect upon first use. More important is whether the desired effect can be reliably reproduced under comparable conditions.
• Good tolerability
  Side effects such as severe restlessness, dizziness, palpitations, drowsiness, or concentration problems should be documented and discussed with a doctor. A high price does not make such side effects less relevant.
• Long-term availability
  A very well-suited strain offers little planning security if it is constantly out of stock. A permanently available alternative may be more sensible for continuous therapy.
• Actual therapy costs
  In addition to the price per gram, the required quantity, shipping costs, possible prescription or treatment costs, and the frequency of strain changes count.
• Expert advice
  Specialized pharmacies can provide information on availability, comparable active ingredient strengths, storage, and possible alternatives. The medical therapy decision remains the responsibility of the treating physician.

CannaRoko for example, offers both personal pickup in Bitterfeld-Wolfen and nationwide shipping, as well as specialized advice on medicinal cannabis.

The most sensible approach is not a spontaneous switch between as many products as possible, but a structured comparison.

For each medically prescribed strain, document:

• Product and batch

• THC and CBD content

• amount applied

• time of application

• desired effect

• actual effect

• time until onset of effect

• duration of perceived effect

• possible side effects

• cost per day

If possible, do not change several factors at once. If the strain, quantity, application temperature, and time of day are changed simultaneously, it will be difficult to determine later what caused the difference.

The cost per treatment day can be easily calculated:

Price per gram × daily quantity in grams = daily product costs

For example, for a strain costing 7.99 euros and a medically determined daily quantity of 0.20 grams, this would be about 1.60 euros per day, or about 47.94 euros in 30 days.

Additionally, the following should be checked:

• Is the strain regularly available?

• Are shipping costs incurred?

• Is there a comparable alternative with a similar THC/CBD profile?

• Will the required amount remain stable over several weeks?

• Does the strain actually improve the defined therapeutic goal?

• Are the costs and perceived benefits in a reasonable relationship?

Another factor is tolerance development. Those who regularly use high amounts of THC may experience a reduced effect with the same amount over time. An independent dose increase is not automatically the right solution. Changes should be discussed with the treating physician.

Expensive cannabis strains are not necessarily better. The price can reflect higher production costs, smaller batches, tight availability, or a specific brand positioning. However, it is not a reliable assessment of therapeutic suitability.

Even a high THC content does not automatically justify a higher price. Very potent flowers can already be available in the medium or low-price segment. At the same time, more THC can increase the risk of unwanted effects and rapid tolerance development.

For patients, therefore, it is not the price per gram alone that is decisive, but the combination of:

• reliable effect

• good tolerability

• required daily amount

• long-term availability

• pharmaceutical quality

• actual monthly therapy costs

The most sensible comparison is not "Which strain is the most expensive?" but:

Which strain reliably achieves the jointly defined therapeutic goal, is well-tolerated, and at reasonable overall costs?